Christopher Brooke
Directeur des opérations chez SwanBio Therapeutics, Inc.
Fortune : 165 734 $ au 30/04/2024
Profil
Christopher Brooke is the founder of Rumpus Therapeutics.
He is currently the Chief Operating Officer at SwanBio Therapeutics, Inc. where he started in 2023.
Prior to this, he was the Chief Operating Officer at Aytu Biopharma, Inc. from 2021 to 2023.
Mr. Brooke received his undergraduate degree from Colgate University and his MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
AYTU BIOPHARMA, INC.
1,05% | 11/08/2023 | 58 357 ( 1,05% ) | 165 734 $ | 30/04/2024 |
Postes actifs de Christopher Brooke
| Sociétés | Poste | Début |
|---|---|---|
SwanBio Therapeutics, Inc.
 SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Directeur des opérations | 16/10/2023 |
Anciens postes connus de Christopher Brooke
| Sociétés | Poste | Fin |
|---|---|---|
| AYTU BIOPHARMA, INC. | Directeur des opérations | 13/10/2023 |
| Rumpus Therapeutics | Fondateur | - |
Formation de Christopher Brooke
| Colgate University | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
SwanBio Therapeutics, Inc.
SwanBio Therapeutics, Inc. BiotechnologyHealth Technology SwanBio Therapeutics, Inc. operates as a gene therapy firm. The company was founded by Tom Anderson, Rachel Salzman, Karen Kozarsky and Florian S. Eichler and is headquartered in Bala Cynwyd, PA. | Health Technology |
| Rumpus Therapeutics | |
| Aytu Biopharma, Inc. |
